INDIGO Announces In Vitro Toxicology Platform

In vitro toxicology platform provides predictive model of liver toxicity. Aims to reduce the high rates of drug-induced liver damage

State College, PA (PRWEB) May 04, 2016

Based on upcyte® human liver cells lines, INDIGO has completed break-through development that decreases donor-to-donor variability while maintaining many Phase I and Phase II enzyme activities, comparable to primary hepatocytes.

Utilizing this unique platform, INDIGO’s services lab can examine your compound’s potential to cause liver toxicity through metabolic activation or by induction of drug metabolism enzymes. Upcyte® hepatocytes contain equivalent activity of several cytochrome P450’s when compared to human hepatocytes, thus making the examination of metabolism-dependent toxicity biologically relevant. INDIGO can strengthen and quantify changes in the expression of target genes regulated by PXR, CAR, AhR, LXR’s, LRH-1, PPAR’s, and Nrf2.

“There is increasing demand to develop more predictive models for liver toxicity,” says Dr. Jack Vanden Heuvel, INDIGO Chief Scientific Officer. “Hepatotoxicity remains a major reason for drug withdrawal from pharmaceutical development and clinical use. These cells offer a very attractive model to predict hepatoxicity caused by drugs and chemicals of environmental concern.”

About INDIGO Biosciences, Inc.
INDIGO Biosciences was founded in 2005 in State College, Pennsylvania, and has established itself as an industry-leading provider of both products and services focused on nuclear receptors. INDIGO offers both screening services and assay kits for the pharmaceutical, biotechnology, agri-business, nutriceutical industries, as well as government research agencies and academic researchers.

For more information on INDIGO’s products or services, please visit indigobiosciences.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/05/prweb13386558.htm